Galectin Therapeutics Inc. 10-Q Summary
Business Context and Reporting Period
Galectin Therapeutics Inc. is a clinical-stage biopharmaceutical company developing galectin-targeting therapies for fibrotic disease, severe skin disease and cancer. The filing covers the three months ended March 31, 2017, with comparative results for the three months ended March 31, 2016. The company had 34,670,684 common shares outstanding as of May 8, 2017.
The lead candidate, GR-MD-02, was primarily being developed for NASH-related liver fibrosis and cirrhosis. The company reported no significant revenues and has operated at a loss since inception.
Key Financial Metrics
| Metric | Q1 2017 | Q1 2016 | Change |
|---|---|---|---|
| Revenue | None significant | None significant | Not applicable |
| Research and development expense | $3.772 million | $4.377 million | Down 14% |
| General and administrative expense | $1.174 million | $2.437 million | Down 52% |
| Total operating expenses | $4.946 million | $6.814 million | Down 27% |
| Operating loss | $4.946 million | $6.814 million | Improved by $1.868 million |
| Net loss | $4.937 million | $6.800 million | Improved by $1.863 million |
| Net loss applicable to common stockholders | $5.209 million | $7.010 million | Improved by $1.801 million |
| Basic and diluted loss per share | $0.15 | $0.24 | Improved |
| Net cash used in operating activities | $3.863 million | $3.490 million | Increased by $0.373 million |
| Cash and cash equivalents, period-end | $13.644 million | $22.356 million | Down $8.712 million year over year |
Margins are not meaningful because the company generated no significant revenue. Interest income was $9,000 in Q1 2017, compared with $14,000 in Q1 2016.
At March 31, 2017, current liabilities were $4.362 million, including $1.346 million of accounts payable and $3.016 million of accrued expenses. The company reported no debt in the filing. Cash provided by financing activities was $2.145 million, consisting of net proceeds from common-stock and warrant issuances.
The balance sheet presents total current assets of $13.997 million at March 31, 2017, equal to cash plus prepaid expenses and other current assets. The December 31, 2016 column shows total current assets of $26.400 million despite listed components totaling $15.794 million; the filing text does not explain this apparent internal inconsistency.
Material Changes Versus the Prior Comparable Period
- Research and development expense declined $605,000, primarily because of lower clinical-trial drug manufacturing and preparation costs, reduced preclinical activity and lower stock-based compensation.
- General and administrative expense declined $1.263 million. The prior-year period included $300,000 of severance and $578,000 of accelerated stock-based compensation related to the termination of the executive chairman in January 2016, as well as higher investor-relations costs.
- Net loss improved by $1.863 million, while net loss applicable to common stockholders improved by $1.801 million.
- Operating cash use increased despite lower reported expenses, principally due to the timing of payments for clinical-trial activities.
- The company issued 1,496,797 common shares under its 2014 at-the-market agreement for approximately $1.945 million of net proceeds and issued 102,368 common shares for $200,000 in a February 2017 private placement. The private placement also included warrants to purchase 76,776 common shares at $5.00 per share.
- Common shares outstanding increased to 34.671 million at March 31, 2017 from 32.913 million at December 31, 2016.
Guidance, Outlook, Risks and Unusual Items
Management stated that the $13.6 million of unrestricted cash at March 31, 2017 was expected to fund currently planned operations through December 31, 2017. Continued operations after existing cash is exhausted depend on additional financing or profitable operations, and no assurance was provided. The company expects losses to continue for the foreseeable future.
The Phase 2b NASH-CX trial enrolled 162 patients at 36 U.S. sites, with top-line data expected in December 2017. The completed NASH-FX trial did not meet its primary or secondary imaging-based endpoints; management attributed this in part to the trial’s short four-month treatment period and limited statistical power. GR-MD-02 was reported as safe and well tolerated in that study.
Early data from investigator-sponsored cancer studies and small, open-label skin-disease studies were described as encouraging, but these results are preliminary and require confirmation in controlled and adequately powered trials. Further psoriasis development was not expected without a strategic partnership.
Key risks include the company’s early development stage, lack of revenue, recurring losses, dependence on external capital, clinical-trial execution and results, regulatory approval, manufacturing and intellectual-property risks, potential inability to secure strategic partnerships, biotechnology-sector competition and stock-price volatility.
Shareholder derivative litigation remained subject to appeal in Nevada after related federal litigation was dismissed. The company could not reasonably estimate potential losses or timing, although it did not believe reasonably possible losses were material based on currently available information. An adverse outcome could nevertheless materially affect a future reporting period.
As of March 31, 2017, the company had 12.249 million outstanding warrants, 4.657 million options and 4.312 million shares issuable upon preferred-stock conversion, or 21.218 million potentially dilutive shares excluded from diluted loss per share because their effect was anti-dilutive.
Investor Verification Checklist
- Verify the apparent December 31, 2016 total-current-assets inconsistency in the balance sheet.
- Verify the timing, size and terms of additional financing needed after the company’s projected cash runway through December 31, 2017.
- Monitor the NASH-CX trial, including the December 2017 data readout, safety results and primary endpoint performance.
- Assess the implications of the unsuccessful NASH-FX endpoints and the limited, uncontrolled evidence from skin-disease and cancer programs.
- Review dilution from outstanding warrants, options, preferred-stock conversion rights and future equity financing.
- Follow the Nevada shareholder litigation appeal and any related demand or potential settlement developments.
- Confirm that the company’s disclosure controls remained effective and review subsequent SEC filings for changes in liquidity, clinical status or contingencies.